The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB 1 receptors and modulated by TRPA1 and Ca v2.2 channels

Hippocampus

Volumn 21, Issue 5, 2011, Pages 554-564

  Koch, Marco ^a   Kreutz, Susanne ^a   Böttger, Charlotte ^a   Grabiec, Urszula ^a   Ghadban, Chalid ^a   Korf, Horst Werner ^a   Dehghani, Faramarz ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Allyl isothiocyanate (AITC); N type voltage gated ca 2+ channels (ca v2.2); Neuroprotection; OHSC; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CALCIUM CHANNEL N TYPE; CANNABINOID 1 RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL N TYPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CHANNEL GATING; DENTATE GYRUS; DOSE RESPONSE; GRANULE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

ANIMALS; BENZOXAZINES; CALCIUM CHANNELS, N-TYPE; CANNABINOIDS; DENTATE GYRUS; MALE; MORPHOLINES; NAPHTHALENES; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TRPC CATION CHANNELS;

EID: 79955089982     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20772     Document Type: Article

References (72)

1. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. 2008. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 28: 1064-1075.
2. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. 2009. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 30: 79-84.
3. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A. 2004. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41: 849-857.
4. Boscia F, Annunziato L, Taglialatela M. 2006. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacol 51: 283-294.
5. Breivogel CS, Griffin G, Di Marzo V, Martin BR. 2001. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
6. 2+ channels. Annu Rev Cell Dev Biol 16: 521-555.
7. Chan GC, Hinds TR, Impey S, Storm DR. 1998. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 18: 5322-5332.
8. Chin C, Lucas-Lenard J, Abadji V, Kendall DA. 1998. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70: 366-373.
9. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, Guglielmotti V, Di Marzo V. 2008. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neurosci 151: 955-968.
10. Darmani NA. 2001. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol 430: 49-58.
11. de Haas AH, Boddeke HW, Biber K. 2008. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56: 888-894.
12. Dehghani F, Hischebeth GT, Wirjatijasa F, Kohl A, Korf HW, Hailer NP. 2003. The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures. Eur J Neurosci 18: 1061-1072.
13. Di Marzo V, Petrosino S. 2007. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18: 129-140.
14. Dolphin AC. 1998. Mechanisms of modulation of voltage-dependent calcium channels by G proteins. J Physiol 506: 3-11.
15. Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, Henze DA, Kane SA, Urban MO. 2008. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain 4: 48.
16. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79.
17. Freund TF, Katona I, Piomelli D. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
18. Gunthorpe MJ, Szallasi A. 2008. Peripheral TRPV1 receptors as targets for drug development: New molecules and mechanisms. Curr Pharm Des 14: 32-41.
19. Hájos N, Freund TF. 2002. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121: 73-82.
20. Hájos N, Ledent C, Freund TF. 2001. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neurosci 106: 1-4.
21. Haller J, Mátyás F, Soproni K, Varga B, Barsy B, Németh B, Mikics É, Freund TF, Hájos N. 2007. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic/glutamatergic synaptic transmission. Eur J Neurosci 25: 2445-2456.
22. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ. 2009. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183-193.
23. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. 2002. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
24. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. 1999. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
25. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, Julius D. 2004. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260-265.
26. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME. 2009. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284: 29817-29827 (The orphan receptor GPR55 is a novel cannabinoid receptor).
27. Katona I, Freund TF. 2008. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
28. Katona I, Sperlágh B, Sík A, Käfalvi A, Vizi ES, Mackie K, Freund TF. 1999. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
29. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, Freund TF. 2001. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. JNeurosci 21: 9506-9518.
30. Kreutz S, Koch M, Ghadban C, Korf HW, Dehghani F. 2007. Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol 203: 246-257.
31. Kreutz S, Koch M, Böttger C, Ghadban C, Korf HW, Dehghani F. 2009. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 57: 286-294.
32. Kohl A, Dehghani F, Korf HW, Hailer NP. 2003. The bisphosphonate clodronate depletes microglial cells in excitotoxically injured organotypic hippocampal slice cultures. Exp Neurol 181: 1-11.
33. Mackie K, Hille B. 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825-3829.
34. Mackie K, Stella N. 2006. Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J 8: E298-E306.
35. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der SM, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di M, V, Behl C, Lutz B. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
36. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
37. McKemy DD, Neuhausser WM, Julius D. 2002. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416: 52-58.
38. Mechoulam R, Lichtman AH. 2003. Neuroscience. Stout guards of the central nervous system. Science 302: 65-67.
39. Mechoulam R, Panikashvili D, Shohami E. 2002. Cannabinoids and brain injury: Therapeutic implications. Trends Mol Med 8: 58-61.
40. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, Muntoni AL, Lutz B, Gessa GL, Marsicano G, Di MV, Pistis M. 2006. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 24: 15-27.
41. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
42. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995.
43. Németh B, Ledent C, Freund TF, Hájos N. 2008. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55, 212-2. Neuropharmacol 54: 51-57.
44. Pacheco MA, Ward SJ, Childers SR. 1993. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 603: 102-110.
45. Panikashvili D, Simeonidou C, Ben Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531.
46. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. 2005. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25: 477-484.
47. Pertwee RG. 1999. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664.
48. Pertwee RG. 2007. GPR55: A new member of the cannabinoid receptor clan? Br J Pharmacol 152: 984-956.
49. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N, Vogel Z, Juknat A. 2009. Differential changes in GPR55 during microglial cell activation. FEBS Lett 583: 2071-2076.
50. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
51. Pozzo Miller LD, Mahanty NK, Connor JA, Landis DM. 1994. Spontaneous pyramidal cell death in organotypic slice cultures from rat hippocampus is prevented by glutamate receptor antagonists. Neurosci 63: 471-487.
52. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. 2009. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12: 1152-1158.
53. 2+) channels by lipids. Cell Calcium 45:589-601.
54. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
55. Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. 2007. Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 36: 82-91.
56. Shen M, Piser TM, Seybold VS, Thayer SA. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16: 4322-4334.
57. Song ZH, Bonner TI. 1996. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49: 891-896.
58. Starowicz K, Cristino L, Di Marzo V. 2008. TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr Pharm Des 14: 42-54.
59. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP. 2008. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225-236.
60. Stella N. 2009. Endocannabinoid signaling in microglial cells. Neuropharmacology 56: 244-253.
61. Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H. 2006. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18: 1584-1594.
62. Stoppini L, Buchs PA, Muller D. 1991. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182.
63. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A. 2003. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112: 819-829.
64. Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K. 2006a. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. JPharmacol Sci 96: 367-375.
65. Sugiura T, Kishimoto S, Oka S, Gokoh M. 2006b. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45: 405-446.
66. Tao Q, Abood ME. 1998. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285: 651-658.
67. Ullrich O, Merker K, Timm J, Tauber S. 2007. Immune control by endocannabinoids-New mechanisms of neuroprotection? J Neuroimmunol 184: 127-135.
68. Vogt C, Hailer NP, Ghadban C, Korf HW, Dehghani F. 2008. Successful inhibition of excitotoxic neuronal damage and microglial activation after delayed application of interleukin-1 receptor antagonist. J Neurosci Res 86: 3314-3321.
69. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. 2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.
70. Wei ET, Seid DA. 1983. AG-3-5: A chemical producing sensations of cold. J Pharm Pharmacol 35: 110-112.
71. Wilson RI, Kunos G, Nicoll RA. 2001. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31: 453-462.
72. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED. 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.